Genomic Health EVP Steven Shak Unloads 7,000 Shares (GHDX)
Genomic Health (NASDAQ:GHDX) EVP Steven Shak sold 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $31.51, for a total value of $220,570.00. Following the completion of the sale, the executive vice president now directly owns 308,283 shares of the company’s stock, valued at approximately $9,713,997. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on GHDX shares. Analysts at Zacks reiterated a “neutral” rating on shares of Genomic Health in a research note to investors on Thursday, December 26th. They now have a $31.00 price target on the stock. Separately, analysts at BMO Capital Markets raised their price target on shares of Genomic Health from $18.00 to $20.00 in a research note to investors on Thursday, November 7th. They now have an “underperform” rating on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Genomic Health from $35.00 to $33.00 in a research note to investors on Wednesday, November 6th. They now have a “hold” rating on the stock. Four investment analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $33.60.
Genomic Health (NASDAQ:GHDX) traded down 1.09% on Friday, hitting $32.54. The stock had a trading volume of 118,905 shares. Genomic Health has a 52-week low of $26.25 and a 52-week high of $38.99. The stock’s 50-day moving average is $30.86 and its 200-day moving average is $32.3. The company’s market cap is $1.000 billion.
Genomic Health (NASDAQ:GHDX) last released its earnings data on Tuesday, November 5th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.06. The company had revenue of $65.99 million for the quarter, compared to the consensus estimate of $64.98 million. During the same quarter in the previous year, the company posted $0.11 earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. On average, analysts predict that Genomic Health will post $-0.13 earnings per share for the current fiscal year.
Genomic Health, Inc (NASDAQ:GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.